HER2 splice variants and their relevance in breast cancer

Mariana Sasso, Francesca Bianchi, Valentina Ciravolo, Eida Tagliafu, Manuela Campiglio
Molecular Targeting Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Abstract

The HER2 gene amplification occurs in 20-30% of breast cancer and is correlated with a poorer prognosis compared to HER2-negative disease due to increased proliferation and metastatic potential. Two major types of receptor inhibitors have been developed for therapy and one for each categories is currently used in clinic: i) the humanized monoclonal antibody trastuzumab, directed against the HER2 extracellular domain; and ii) the EGFR/HER2 dual tyrosine kinase inhibitor lapatinib. However, patients may develop resistance to drugs and show disease progression. Several mechanisms of resistance have been explored and are still under investigation. Here, we focus our attention on the role played by the alternative splicing forms of HER2 in mediating HER2 oncogenic activity and in conditioning the response to HER2 therapies. Three HER2 splice variants have been described so far; the p100 and the herstatin give rise to two secreted proteins of 100 kd and 68 kd, respectively, that act as cell growth inhibitors. The third splice form of HER2 gene is the Δ16HER2, encoding for a receptor lacking exon16, whose absence determines constitutive active dimers with transforming activity in vitro and in vivo. The Δ16HER2 binds to trastuzumab to a lesser extent, due to conformational changes of the extracellular domain and its levels are supposed to increase proportionally to the increasing of the HER2 wild-type copy numbers in human primary breast cancers. Finally, HER2 carboxy-terminal fragments (CTFs), generated by alternative initiation of translation, were observed in breast cancer patients. In particular, 611-CTF, activating multiple signaling pathways since it is expressed as a constitutively active homodimer, was suggested to be a potent oncogene capable of promoting mammary tumour progression and metastasis. Despite the evidences of a potential role of the naturally occurring inhibitors p100 and herstatin on the wild-type HER2 and its signaling pathway, to date do not seem to have a possible clinical development. To date the most promising forms currently under investigation that could have a key role in determining the increased HER2-positive tumours aggressiveness and toward the development of bio-drugs are the HER2Δ16 and the CTFs.

HER2 features and relevance in breast cancer disease

HER2 (also known as c-HER-2 or HER2/neu) is a proto-oncogene mapped to the chromosome 17q21,2 encoding a 1255 amino acid transmembrane glycoprotein of 185 kDa designated as HER2 or p185HER2 (Figure 1A) that, together with its relatives HER1, HER3 and HER4, belongs to HER family of receptor tyrosine kinases (RTKs).3

The HER receptors share a similar structure, comprising an extracellular binding domain, a transmembrane lipophilic segment, and except for HER3, a functional intracellular tyrosine kinase domain with a regulatory carboxy-terminal tail. These RTKs are activated by the binding of specific EGFR-like growth factors,4 but none of them directly binds to HER2. Ligands binding induce receptor homo- and hetero-dimerization and tyrosine autophosphorylation, which are obligatory steps in signal activation.5 Despite orphan of a specific soluble ligand, HER2 is the preferred heterodimerization partner of the other three HER members,6 since it adopts a fixed conformation resembling a ligand-activated state, allowing it to dimerize in the absence of ligand.7 Once activated, it is able to induce signaling that promotes proliferation and survival.8 HER2 amplification leads to progression from normal breast epithelia to invasive cancer cells.9,10 Accordingly, gene expression analysis showed that the HER2-positive tumours clustered as a specific subset, mainly characterized by the lack of expression of genes associated with hormone receptor signaling pathways and high-level expression of a cluster of genes associated with proliferation. This subgroup was clearly distinguished from the other aggressive phenotype (to which triple negative breast cancer mainly belongs), defined by lacking of HER2 expression and both estrogen and progesterone receptors, from luminal, expressing estrogen receptor, and normal-like subset.11 However, the HER2 overexpression is necessary but not sufficient to induce malignant transformation, as clearly demonstrated by rat proto-oncogene HER2/neu transgenic mice either bearing additional alterations in HER2 gene sequence12,13 or cross-bred with mice transgenically expressing other cancer-related alterations.14-16

The increased HER2 expression levels in breast carcinoma respect to normal breast tissue and the evidence of its driving role in HER2-positive tumours progression made HER2 an ideal target for specific therapeutic approaches. Indeed, in 1998 trastuzumab, a recombinant humanized monoclonal antibody directed to the extracellular domain of the HER2 protein, was the first monoclonal antibody to gain the FDA approval for clinical treatment of women with HER2 positive metastatic breast cancer.17 Since 2006 trastuzumab was also approved for adjuvant treatment of patients with early breast cancer and promising evidences showed its effect also in preoperative setting.18,19 The other HER2-targeted therapy approved for clinical use is the EGF/HER2 dual tyrosine kinase inhibitor lapatinib, a competitor of ATP in the kinase domain of HER2 that impairs the transmission of its signal.20,21 Based on promising clinical trials data,22,23 in 2007 FDA and EMEA approved the use of lapatinib in combination with capcitabine in patients with advanced or metastatic HER2-positive breast cancers.24 Despite objective clinical results, obtained with biologics so far anti-HER2 agents show clinical benefit in about 50% of patients with HER2-positive breast carcinomas.25-27 Extensive literature aimed to clarify the mechanisms of trastuzumab efficacy and resistance in different breast cancer clinical settings has been published so far,28 and a huge effort has been devoted to the search for markers of response to therapy. In spite of high investments, none of the markers described as associated to therapy sensitivity/resistance were sufficiently

Conflict of interest: the authors report no conflicts of interest.

Received for publication: 4 June 2011.
Revision received: 7 June 2011.
Accepted for publication: 7 June 2011.

This work is licensed under a Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 3.0).

©Copyright M. Sasso et al., 2011
Licensee PAGEPress, Italy
Journal of Nucleic Acids Investigation 2011; 2:e9
doi:10.4081/jnai.2011.e9

Correspondence: Manuela Campiglio, Molecular Targeting Unit, Dept. of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, via Venezian 1, 20133 Milan, Italy.
Tel. +390223905121 - Fax. +390223902692.
E-mail: manuela.campiglio@istitutotumori.mi.it

Key words: HER2, breast cancer, HER2delta16, Herstatin, ECD.
reliable to be introduced into the clinical setting.

It is now clear the importance of a persistent targeting of HER2 axis in breast cancer and, therefore, to develop additional therapeutic strategies to better impair HER2 activity. This will be reached through a more precise delineation of both HER2 biology and HER2 drugs mechanisms of action in tumours, especially after the recent demonstration of improved overall survival of gastric patients bearing HER2 amplification and, therefore, trastuzumab-treated in phase III trial. Indeed, it is unlikely that the optimization of both treatment protocols design and duration will be sufficient to overcome HER2 resistance. It is, therefore, necessary to come back to dissect HER2 pathway and unravel key features contributing to its transforming capacity. In the present review, we focus our attention on the role played by the alternative splicing forms of HER2 in mediating HER2 oncogenic activity and in conditioning the response to HER2 therapies (summarized in Table 1), in breast cancer.

**p100: ECD from the splicing processing**

The first described HER2 splice variant was the extracellular secreted 100kDa fragments named p100. In 1993 Scott et al. described a 2.3 kb variant of HER2 mRNA encoding the first 633 amino acids (aa) containing almost the entire HER2-ECD (extra cellular domain) (subdomains I-IV) (Figure 1B). Many transmembrane growth factor receptors have been reported to have soluble, ligand-binding receptor forms detectable in the conditioned media of tumour cells and in biological fluids. These soluble receptor proteins arise through proteolytic cleavage of membrane-anchored full-length receptors and/or by alternative splicing or other gene rearrangements that usually produce novel transcripts which encode for proteins containing parts of the ECD but lacking the transmembrane and cytoplasmic domains of the full-length receptor.

p100 has been described to interfere with oncogenic HER2 activity through different mechanisms. Collectively, it acts as inhibitor of tumour cell proliferation and of growth factor-mediated tumour cell proliferation. They transfected MCF7 breast cancer cells, since MCF7 does not endogenously express this spliced HER2 mRNA but only low levels of the full-length HER2 protein. Doxycycline-regulated expression of the transfected HER2-ECD cDNA induced the HER2-ECD-mediated inhibition of spontaneous proliferation as well as inhibition of heregulin-mediated proliferation and signal transduction. As expected, significant amounts of p100 protein in the conditioned media has been detected, demonstrating that the HER2-ECD protein was effectively secreted in transfected MCF7 cells. Likewise, in MKN7, a gastric tumour cell line with very high expression levels of the splice variant as well as full-length HER2 proteins, ribozyme-targeting of the endogenously expressed p100 mRNA splice variant demonstrated reduction of p100-mediated inhibition of proliferation in soft agar accordingly with a reduced downstream signal-transduction. Indeed, p100 over-expression resulted in a time-delay and decrease of heregulin-mediated phosphorylation of the HER4 receptor, followed by a similar inhibition of downstream signaling events such as activation of p44/p42 MAP-kinases.

Actually, several evidences point to HER2-ECD levels in serum as biomarker for HER2 over-expressing cancer aggressiveness and therapy response. Indeed, HER2-ECD is easily detectable using an enzyme-linked immunosorbent assay (ELISA). The potential in vivo role of soluble truncated HER2 proteins was investigated in gastric tumours, where a trend was found towards reduced HER2-ECD expression in tumours with a more aggressive phenotype. Clearly, the great part of data came from breast cancer studies where serum ECD levels have been proposed as predictive marker for trastuzumab treatment. Several studies have been performed providing contrasting conclusions, therefore, the utility of serum ECD values at baseline and during therapy as a potential marker of tumour response or progression is actually a matter of debate.

**Herstatin: a naturally occurring HER2 inhibitor**

In 1999 Doherty et al. described a secreted protein of 68 kDa, named herstatin, as the product of an alternative HER2 transcript which is generated by retention of intron 8 in HER2 alternative mRNA (Figure 1C). This transcript generates a protein that consists of the first 340 aa-residues identical to N-terminal subdomains of HER2, followed by a novel C-terminus of 79 aa-residues. Herstatin appears...
to be a naturally occurring inhibitor of HER-2, because it disrupts dimers, reduces tyrosine phosphorylation of HER2, and inhibits the anchorage-independent growth of transformed cells that overexpressed HER2. Azios et al. underlined the importance of herstatin in cancer disease since its ectopic expression leads not only to the interruption of constitutive activation of HER2, but also to the lack of het- erodimerization of HER2/HER3 and EGFR activation. The ability of herstatin to suppress colony formation of HER2 or EGFR-overexpressing cells suggested its potential use in limiting tumour cell growth driven by these receptors. In 2005 Hu et al. described the three dimensional structure of herstatin and its interaction binding site with HER2 extra-cellular domain. The interaction of herstatin and HER2 on the cell surface was accompanied by an increased co-localization of HER2 and herstatin in the cytoplasm, suggesting that HER2/herstatin complex formation may prevent transit from endoplasmic reticulum to cell surface of HER2. The intracellular sequestering of HER2 by herstatin may be a possible naturally occurring inhibitory mechanism controlling cell growth Table 1.

Several studies investigated the presence of herstatin in normal and cancer cellular lines. Herstatin mRNA was found expressed in normal human fetal kidney and liver tissue, but it appears to be expressed at reduced levels respect to the HER2 mRNA in breast carcinoma cells that contain amplification of HER2. A further study investigated the herstatin mRNA level and its protein expression in breast carcinoma tissues compared to their normal breast tissues. In this context, it has been shown that herstatin mRNA and protein are expressed in non-cancerous breast, in areas adjacent to breast carcinoma. This characteristic expression pattern of herstatin in non-cancerous breast tissues might contribute to the normally endogenous HERs-inhibition system, because there is a local need for HERs inhibition in differentiating ductal epithelia. An additional study showed that breast cancer tissues express Herstatin mRNA, but the protein is absent in 75% of breast carcinomas, which indicates that cancer cells are protected by not yet established intrinsic mechanisms against the putative growth-inhibitory effects of this molecule. The authors speculate that, if this negative regulation occurs at the pre-translational level, then it seems possible that exogenous administration of i.e pan-HER antibodies would help in blocking tumour growth. If the protein is produced but released from the cells, then it seems possible that the mechanism, which impairs the endogenous inhibitor activity, will also apply to the exogenous administered antibody as well. Most importantly, if 25% of breast carcinomas grow in the presence of an endoge- nous pertuzumab-like inhibitor, which is produced in high amounts in some cases with adverse prognostic parameters (HER2 overexpression, activated Akt/PKB, and blocked p21CIP1/WAF1), then it remains questionable whether these cancers would benefit from exogenous attempts to disrupt HER2 dimeriza- tion. It has been shown that Herstatin expression inhibited the in vitro growth of the human glioblastoma cell line U87MG in a dose responsive manner and that prevented the tumours formation. Additionally, authors demonstrated that human glioblastoma bearing truncated EGFR were resistant to Herstatin, suggesting that herstatin may have utility against glioblastoma driven by the EGFR.

### Table 1. Different HER2 isoforms with their biological activities and target therapies.

<table>
<thead>
<tr>
<th>HER2 isoforms</th>
<th>Biological activity</th>
<th>Targeted therapies used</th>
</tr>
</thead>
<tbody>
<tr>
<td>p110</td>
<td>Inhibition of tumour cells proliferation</td>
<td>Contrasting data on trastuzumab</td>
</tr>
<tr>
<td>Δ16HER2</td>
<td>Oncogenic capability; increase of metastatic potential</td>
<td>Lower trastuzumab efficacy, de novo tanoxifen resistance</td>
</tr>
<tr>
<td>CTFs 611-CTF</td>
<td>Increase of metastatic potential</td>
<td>Lapatinib response</td>
</tr>
<tr>
<td>687-CTF</td>
<td>Inactive</td>
<td>Trastuzumab resistance</td>
</tr>
<tr>
<td>648-CTF</td>
<td>The same of full-length HER2</td>
<td></td>
</tr>
</tbody>
</table>

### Δ16HER2: the real player in HER2 tumourigenesis?

An important issue concerning HER2 over-expression in human primary breast cancers is that this genetic alteration, primarily due to gene amplification, is relevant but not sufficient to induce transformation. The expres- sion of an alternatively spliced human HER2 isoform encoding a receptor lacking exon 16, which immediately precedes the transmembrane domain, and so called Δ16HER2 (Figure 1D). It was reported this splice variant accounts only for 4-9% of the total HER2 tran- scripts, but transgenic studies provided direct evidence of the key role of the Δ16HER2 splice variant in HER2 transforming activity. In trans- generic mice, tumours arose only when the oncprotein carried small deletions in the extracellular domain, thus promoting HER2/neu transforming activity through for- mation of intermolecular disulfide bonds. Indeed, mammary-specific expression of the rat HER2/neu gene induces tumours only when accompanied by in-frame activating deletions of cysteine residues within the wild-type HER2/neu extracellular domain. The loss of these cysteine residues appears to induce a conformational change in the HER2 extracel- lular domain that promotes intermolecular disul- fide bridges and, in turn, constitutively acti- vates stable HER2 homodimers on tumour cell surface able to drive mitogenic signaling. Athymic mice injected with Δ16HER2-HEK293 transfectants developed tumours, whereas mice injected with HEK293 control cells ectopi- cally overexpressing only WT HER2, did not. In this model, Δ16HER2 was constitutively active supporting the hypothesis that its tumourigenic potential is due to the ability to form disulfide-bridged homodimers. More recently, Mitra et al. confirmed the same behavior in a breast cancer model. Indeed, they described stable dimers in MCF7 cells transfected with Δ16HER2. As expected, ectopic Δ16HER2 expression led to increased activa- tion of multiple oncogenic pathways, e.g., FAK, Src kinase, phosphatidylinositol 3-kinase/AKT, and mitogen-activated protein kinase, as compared to cells expressing WT HER2. The activa- tion of these oncogenic cascades results in a dramatical increase of Δ16HER2-MCF7 migra- tion and invasion. The most interesting data were the positive correlation between Δ16HER2 expression and positive lymph nodes in patients with HER2-positive tumours high- lighting Δ16HER2 as a critical feature for HER2-breast cancer progression. This study also anticipated the potential clinical implica- tions of Δ16HER2 variant expression in anti- HER2 targeted drugs susceptibility. Castiglioni et al. demonstrated the lower reactivity of trastuzumab, in comparison with other anti- HER2/ECDF Mabs binding to different HER2/ECDF epitopes. These finding suggested that Δ16HER2 expression could be relevant for HER2-targeted therapies efficacy. This hypothes- isis is consistent with clinical findings indicat- ing that wild-type HER2 gene amplification in human primary breast cancers determined a proportional increase in Δ16HER2 levels. Therefore, we can speculate that decreased susceptibility to trastuzumab observed in breast cancer patients with HER2 FISH ratios >1.5 (Table 1) can be attribute to their high expression level of Δ16HER2. Transformation associated with HER2 overexpression might
reflect the increase in absolute levels of this splice variant to a critical threshold for constitutive activation of HER2.

Besides the resistance to anti-HER2 therapy, Δ16HER2 was described as involved in endocrine resistance in HER2-positive/ER-positive breast carcinomas (Table 1). These tumours, that account for half of HER2 positive tumours, represent a challenge for the oncological treatment, since more than 70% exhibited de novo tamoxifen resistance and, indeed, continue to grow even after estrogen depletion. Preclinical studies demonstrated that Δ16HER2, but not wild-type HER2, promotes estrogen-independent growth and the novel resistance to tamoxifen treatment in breast cancer cells in vivo and in vitro. To date, two mechanisms can explain the acquisition of hormone resistance in breast cancer mediated by HER2Δ16. In the first, HER2Δ16 transfected breast cancer tamoxifen-treated cells were found to up-regulate BCL-2 expression mainly through the suppression of miR-15a/16 compared with tamoxifen-sensitive cell lines. Normally, BCL-2 translation is repressed by binding of miR-15a or miR-16 to a seed sequence in BCL-2 mRNA 3′-untranslated regions, and loss of miR-15a/16 in several cancer cell lines and tumours is associated with BCL-2 upregulation and resistance to therapy. Consistently, BCL-2 is upregulated in HER2Δ16 expressing tamoxifen-resistant cells where levels of miR-15a/16 were reduced. Authors established an in vivo model that revealed the inability of wild-type HER2 pre-clinical models to fully recapitulate the aggressive and variable clinical nature of HER2-positive breast tumours. Indeed, similarly to clinical observations, HER2Δ16-expressing xenografts are both tamoxifen resistant and estrogen independent, whereas consistent with other reports, HER2-expressing xenografts display only partial acquired tamoxifen resistance and remain estrogen-dependent. The second mechanism is based on the down-regulation of mir-342 observed in breast cancer cells expressing HER2Δ16 and in primary breast tumours of patients who failed tamoxifen therapy. Mir-342 controlled expression of genes involved in tamoxifen mediated response in breast cancer cells and, indeed, its restoration in MCF7/HER2Δ16 sensitized these cells to tamoxifen-induced apoptosis with a dramatic reduction in cell growth. HER2Δ16 was definitely demonstrated to be sufficient per se for mammary tumours development as we recently reported. We established the first mouse line that transgenically expresses both human Δ16HER2 and firefly luciferase genes. A higher tumour incidence, a more rapid tumour growth, as well as a significantly shorter latency period (15.11 vs 28.6 weeks) in Δ16HER2-LUC transgenic mice were observed, as compared with MMTVhuHER2, the other mouse model transgenic for the human wild-type HER2. The signaling activity of over expressed Δ16HER2-LUC revealed that the oncogenic properties of Δ16HER2 were mediated through activation of Src kinase.

Notably, only 5 copies were found to be sufficient to drive neoplastic transformation of mammary epithelial cells in Δ16HER2-LUC mice, whereas 30-50 wtHER2 transgene copies are required to induce breast cancer in about 80% of MMTV-wtHER2 transgenic mice.

All these findings demonstrated that Δ16HER2 splice variant could actually represent the transforming form of HER2 oncoproteins. Therefore, the role of HER2Δ16 in HER2-driven breast tumours progression and therapy response could be underestimated. There is the need to develop screening test for HER2Δ16 expression in cancer tissues but, most of all, to find compounds able to interfere with its binding to HER2 receptor, to try to overcome the HER2Δ16 induced resistance.

### Carboxy-terminal fragments: besides HER2 splicing processing

A subgroup of HER2-positive patients expresses a series of carboxy-terminal fragments (CTFs) of HER2. HER2 CTFs can be generated at least by two independent mechanisms: proteolytic shedding and alternative initiation of translation. In the first scenario, metalloproteases shed the extracellular domain of HER2 at a site proximal to the transmembrane domain, generating a 95- to 100-kDa fragment, known as p95HER2, that starts at alanine 648. Alternative initiation of translation of the mRNA encoding HER2 from 2 internal initiation methionine at positions 611 and 687 (codons numbered according to the full-length molecule) generates two additional p95HER2 fragments of 100 to 115 kDa and 90- to 95-kDa, respectively known as 611-CTF (Figure 1E) and 687-CTF (Figure 1F). They differ in a stretch of 76 amino acids, which includes the transmembrane domain and a cysteine-rich short extracellular domain. Even though lacking a signal peptide, the 611-CTF fragment is efficiently incorporated into the secretory pathway and transported to the plasma membrane. Instead, the 687-CTF fragment can be found both in the cytoplasm and nucleus.

Pedersen and colleagues analyzed the activity of the individual p95HER2 (Table 1). They showed that the soluble intracellular 687-CTF fragment, despite having an intact kinase domain, was inactive. In contrast, the two CTFs containing the transmembrane domain, 648- and 611-CTFs, can activate several intracellular signal transduction pathways. Interestingly, the level of activation of these pathways is quite different between the two CTFs. 611-CTF activates the mitogen-activated protein kinase and the Akt pathways to a greater extent respect to 648-CTF, because it constitutively forms homodimers maintained through disulfide bonds. In contrast, 648-CTF does not seem to form homodimers, and its activity is compatible with that of full-length HER2. As a result, expression of the 611-CTF fragment leads to the regulation of a specific set of genes. Several of these genes, such as MMP1, ANGPT1, MET, CD44, PLAU, EPHA2, ITGA2, ITGFB, TGFα, and IL-11, are causally involved in the metastatic progression.

Moreover, cortactin, a cytoskeleton-binding protein involved in the regulation of cell migration, was identified as a phosphoprotein regulated by 611-CTF. The authors showed that expression of 611-CTF leads to an increase in the phosphorylation of cortactin and, at least, to an increase in breast cancer cells motility (Table 1).

According with all this evidence, it has been shown that breast cancer patients expressing CTFs have worse prognosis and are more likely to develop nodal metastasis compared with patients expressing predominantly full-length HER2. An early study by Christianson and colleagues showed that the expression of p95HER2 (611-CTF; 648-CTF) in breast tumours correlated with metastasis to the lymph nodes. Several subsequent studies supported that p95HER2 may be used as a biomarker of an aggressive subtype of HER2-positive breast cancer. Retrospective studies showed that tumours expressing p95HER2 tend to be resistant to treatment with trastuzumab but do respond to lapatinib. The effectiveness of lapatinib on p95HER2-positive tumours is not surprising because the tyrosine kinase inhibitor also blocks the activity of the p95HER2 fragments. Therefore, tyrosine kinase inhibitors may be a good therapeutic approach to treat p95HER2-positive tumours. Because both the 95- to 100-kDa and the 100- to 115-kDa transmembrane p95HER2 fragments lack the epitope recognized by trastuzumab, an obvious explanation for the lack of response to the antibody in p95HER2-positive tumours is that expression of these fragments drives tumour growth even under treatment with trastuzumab.

### Conclusion and perspective

Despite the evidence of a potential role of the naturally occurring inhibitors p100 and herstatin on the wild-type HER2 and its signal-
References


7. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptor, is a mediator of lateral signaling. EMBO J 1997;16:1647-55.


